Casdin Partners Master Fund, L.P.
SEC-identified person · CIK 1534265 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Sema4 Holdings Corp. WGS | Director | filed 2023–2026 |
| Biolife Solutions INC BLFS | Officer | filed 2018–2026 |
| Standard Biotools INC. LAB | Director | filed 2022–2025 |
| 2Seventy bio, Inc. TSVT | Director | filed 2024–2025 |
| Maxcyte, INC. MXCT | Officer | filed 2021–2022 |
| Tenaya Therapeutics, Inc. TNYA | Officer | filed 2021–2021 |
| Absci Corp ABSI | Director | filed 2021–2021 |
| Verve Therapeutics, Inc. VERV | Officer | filed 2021–2021 |
| Decibel Therapeutics, Inc. [DBTX] | Officer | filed 2021–2021 |
| Fulcrum Therapeutics, Inc. FULC | Officer | filed 2019–2019 |
| Constellation Pharmaceuticals INC CNST | Officer | filed 2018–2018 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.